EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early-Phase Activation of Epithelial–Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Alessia Belloni iD, Lorenza Tamberi iD, Laura Graciotti iD, Tatiana Spadoni iD, Giulia Matacchione iD, Chiara Giordani iD, Angelica Giuliani iD, Elisa Chiadini iD, Laura Capelli iD, Eleonora Donno, Camilla Sbrighi, Michele Zanoni und 5 weitere

International Journal of Molecular Sciences · 11.07.2026 · 27 (14) · 6207

DOI: 10.3390/ijms27146207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.07.2026. Verfasst von Alessia Belloni und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Sciences (DISCLIMO), Polytechnic University of Marche, 60121 Ancona, Italy. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial–mesenchymal transition (EMT) emerged as a phenotypic change associated with the resistance to epidermal growth factor receptor tyrosine kinase inhibitors, both in vitro and in vivo. The mechanisms underlying this biological process have not yet been fully understood. E-cadherin loss, N-cadherin, and vimentin increase are the main markers characterizing EMT, together with the expression of some transcription factors, such as Snail, Slug, Zeb1, Zeb2, and Twist. In this study, we explore the expression of these markers in lung cancer cell lines bearing wild-type or mutated epidermal growth factor receptor (EGFR), A549 and PC9, respectively. We treated PC9 cells with Gefitinib or Osimetinib, alone or combined with the transforming growth factor beta (TGF-β). We evaluated the expression of E-cadherin, N-cadherin, vimentin, and the transcription factors at 24 and 96 h timepoints, to verify the role of EMT in the early phases of the treatment with tyrosine kinase inhibitors (TKIs). At the 96 h timepoint, we found that in PC9 cells, the treatment with gefitinib or osimertinib, regardless of TGF-β, induces E-cadherin reduction and N-cadherin increase, similar to the effects induced by TGF-β in A549 cells at 24 h. Among the transcription factors, at 96 h, Slug mainly increases when PC9 cells are treated with gefitinib or osimertinib. These results imply that changes in the expression of these epithelial–mesenchymal transition markers may have facilitated the development of drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionLung NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsCell Line, TumorGefitinibCadherinsGene Expression Regulation, NeoplasticVimentinTransforming Growth Factor betaTranscription FactorsA549 Cells

Stichwörter der Autor:innen

epithelial-to-mesenchymal transitiongefitinibnon-small cell lung cancerosimertinibtyrosine kinase inhibitors

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsGefitinibCadherinsVimentinTransforming Growth Factor betaEGFR protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Clinical and Molecular Sciences (DISCLIMO), Polytechnic University of Marche, 60121 Ancona, Italy.
  • Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, 60121 Ancona, Italy.
  • Clinic of Laboratory and Precision Medicine, National Institute of Health and Sciences on Ageing (IRCCS INRCA), 60127 Ancona, Italy.
  • Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

ORCID-Profile: Alessia Belloni, Lorenza Tamberi, Laura Graciotti, Tatiana Spadoni, Giulia Matacchione, Chiara Giordani, Angelica Giuliani, Elisa Chiadini, Laura Capelli, Matteo Canale, Giuseppe Bronte

Förderung

  • Italian Ministry of University and Research

Zitieren

APA

Belloni, A., Tamberi, L., Graciotti, L., Spadoni, T., Matacchione, G., Giordani, C., Giuliani, A., Chiadini, E., Capelli, L., Donno, E., Sbrighi, C., Zanoni, M., Ulivi, P., Rippo, M. R., Crinò, L., Canale, M., & Bronte, G. (2026). Early-Phase Activation of Epithelial–Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences, 27(14), 6207. https://doi.org/10.3390/ijms27146207

Vancouver

Belloni A, Tamberi L, Graciotti L, Spadoni T, Matacchione G, Giordani C, et al. Early-Phase Activation of Epithelial–Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. International Journal of Molecular Sciences. 2026;27(14):6207. doi:10.3390/ijms27146207

BibTeX
@article{Belloni2026,
  author = {Belloni, Alessia and Tamberi, Lorenza and Graciotti, Laura and Spadoni, Tatiana and Matacchione, Giulia and Giordani, Chiara and Giuliani, Angelica and Chiadini, Elisa and Capelli, Laura and Donno, Eleonora and Sbrighi, Camilla and Zanoni, Michele and Ulivi, Paola and Rippo, Maria Rita and Crinò, Lucio and Canale, Matteo and Bronte, Giuseppe},
  title = {Early-Phase Activation of Epithelial–Mesenchymal Transition in Lung Cancer Cells Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6207},
  doi = {10.3390/ijms27146207}
}
Kostenlos starten →